{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:37:34Z","timestamp":1761187054748,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100024217","name":"Osaka International Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.gore.2025.101924","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T21:17:46Z","timestamp":1755811066000},"page":"101924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immune checkpoint inhibitor-related myocarditis during DUO-E regimen for endometrial cancer: The first case report in gynecologic oncology"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9788-275X","authenticated-orcid":false,"given":"Eri","family":"Yamabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Hisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Kitai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2025.101924_b0005","article-title":"Immune checkpoint inhibitor therapy and myocarditis: a new challenge","volume":"45","author":"Atallah-Yunes","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.gore.2025.101924_b0010","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1161\/CIRCRESAHA.109.213157","article-title":"Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy","volume":"106","author":"Baldeviano","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.gore.2025.101924_b0015","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.gore.2025.101924_b0020","first-page":"113","article-title":"Abatacept for Severe Immune Checkpoint Inhibitor\u2013Associated Myocarditis","volume":"61","author":"Salem","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.gore.2025.101924_b0025","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gore.2025.101924_b0030","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jacc.2011.09.074","article-title":"Update on myocarditis","volume":"59","author":"Kindermann","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.gore.2025.101924_b0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.gore.2025.101924_b0040","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.gore.2025.101924_b0045","first-page":"30","article-title":"Fulminant myocarditis following anti\u2013PD-L1 antibody (durvalumab) treatment in non-small cell lung cancer: an autopsy case report","volume":"181","author":"Nishikawa","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.gore.2025.101924_b0050","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gore.2025.101924_b0055","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.gore.2025.101924_b0060","first-page":"385","article-title":"Myocarditis in the setting of Cancer Therapeutics: Proposed Algorithms for Diagnosis and Management","volume":"37","author":"Mahmood","year":"2019","journal-title":"Cardiol. Clin."},{"key":"10.1016\/j.gore.2025.101924_b0065","article-title":"Immune checkpoint inhibitor cardiovascular toxicity in the real world: a community-based analysis","volume":"9","author":"Tang","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.gore.2025.101924_b0070","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.gore.2025.101924_b0075","first-page":"609","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"143","author":"Zhang","year":"2021","journal-title":"Circulation"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925001493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925001493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:08:19Z","timestamp":1761185299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578925001493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":15,"alternative-id":["S2352578925001493"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2025.101924","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor-related myocarditis during DUO-E regimen for endometrial cancer: The first case report in gynecologic oncology","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2025.101924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101924"}}